Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 17/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490941 | 0.85 | AAK1 (0.40) | AAK1LATS1 | |
| SCHEMBL4299216 | 0.82 | LATS1 (0.45) | AAK1LATS1 | |
| SCHEMBL1490726 | 0.81 | CFTR (0.32) | — | |
| SCHEMBL1490782 | 0.80 | CYP1A2 (0.36) | AAK1LATS1CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL1490846 | 0.79 | CYP1A2 (0.36) | AAK1LATS1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2743933 | 0.77 | MEN1 (0.47) | AAK1LATS1 | |
| SCHEMBL1491010 | 0.75 | AAK1 (0.34) | AAK1 | |
| SCHEMBL3178388 | 0.72 | MAPK1 (0.34) | — | |
| SCHEMBL21564436 | 0.71 | LATS1 (0.43) | AAK1LATS1 | |
| SCHEMBL29890985 | 0.71 | LATS1 (0.43) | AAK1LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| WO-2006038923-A2 | ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | AAK1 2808/4885LATS1 3526/4885CYP1A2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.